Collegium Pharmaceutical, Inc COLL
We take great care to ensure that the data presented and summarized in this overview for COLLEGIUM PHARMACEUTICAL, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding COLL
View all-
Black Rock Inc. New York, NY5.79MShares$266 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY2.83MShares$130 Million1.63% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.39MShares$110 Million1.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.23MShares$102 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.6MShares$73.5 Million0.08% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA1.5MShares$69.1 Million0.18% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.31MShares$60.2 Million0.02% of portfolio
-
State Street Corp Boston, MA1.29MShares$59.5 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA1.28MShares$59 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X0910KShares$41.9 Million0.02% of portfolio
Latest Institutional Activity in COLL
Top Purchases
Top Sells
About COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Insider Transactions at COLL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 08
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
17,600
-7.53%
|
$844,800
$48.28 P/Share
|
|
Dec 08
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,600
+12.68%
|
$264,000
$15.9 P/Share
|
|
Dec 05
2025
|
Rita J. Balice Gordon |
SELL
Open market or private sale
|
Direct |
3,650
-6.49%
|
$171,550
$47.03 P/Share
|
|
Nov 12
2025
|
Vikram Karnani President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,983
-8.48%
|
$422,201
$47.35 P/Share
|
|
Nov 12
2025
|
John A. Fallon |
SELL
Open market or private sale
|
Direct |
34,853
-35.03%
|
$1,638,091
$47.21 P/Share
|
|
Nov 12
2025
|
John A. Fallon |
BUY
Exercise of conversion of derivative security
|
Direct |
34,853
+16.24%
|
$418,236
$12.91 P/Share
|
|
Nov 06
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
30,000
-9.87%
|
$1,200,000
$40.83 P/Share
|
|
Aug 29
2025
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
17,478
-19.92%
|
$664,164
$38.42 P/Share
|
|
Aug 18
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
16,389
-13.66%
|
$622,782
$38.21 P/Share
|
|
Aug 18
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,389
+12.02%
|
$344,169
$21.34 P/Share
|
|
Aug 15
2025
|
Gino Santini Director |
SELL
Open market or private sale
|
Direct |
5,405
-5.38%
|
$199,985
$37.19 P/Share
|
|
Aug 15
2025
|
Gino Santini Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.99%
|
$195,000
$13.45 P/Share
|
|
Aug 13
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,861
-4.48%
|
$184,718
$38.03 P/Share
|
|
Aug 13
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,861
+4.29%
|
$102,081
$21.34 P/Share
|
|
Aug 13
2025
|
Rubric Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
25,000
-0.79%
|
$925,000
$37.85 P/Share
|
|
Aug 08
2025
|
John Gordon Freund Director |
SELL
Open market or private sale
|
Indirect |
11,659
-33.51%
|
$396,406
$34.36 P/Share
|
|
Jun 09
2025
|
John Gordon Freund Director |
SELL
Open market or private sale
|
Direct |
6,601
-8.54%
|
$198,030
$30.62 P/Share
|
|
Jun 09
2025
|
John Gordon Freund Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+16.26%
|
$195,000
$13.45 P/Share
|
|
May 15
2025
|
John Gordon Freund Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+13.59%
|
-
|
|
May 15
2025
|
Rita J. Balice Gordon |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+14.82%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 424K shares |
|---|---|
| Exercise of conversion of derivative security | 171K shares |
| Open market or private sale | 354K shares |
|---|---|
| Payment of exercise price or tax liability | 110K shares |